MATTO seminars

Dear MATTO members,

You are invited to a MATTO seminar on Wednesday, October 10, 2018 at 3:30pm-5pm:

“Reflections from a Recovering Tech Transfer Professional: Pharma Edition”

The seminar will take place  in the Havana room, 5th Floor, CIC, One Broadway, Kendall Square, Cambridge, MA 02142

Come and hear a panel of business development leaders that have spent time in Tech Transfer Offices as well as Industry, both large pharma and biotech.  The panelists will reflect on learnings from their hands-on experience in settings across the life sciences ecosystem, how they might do things differently based on seeing licensing and partnering from multiple perspectives, and provide tips and advice on how Tech Transfer Offices may be able to increase their success in licensing/partnering with industry.

Speakers:

  • Christine Jost-Price Director, Sanofi Genzyme Transactions
  • Aaron Schwartz, Director, Search & Evaluation, Global Drug Discovery, Novo Nordisk
  • Maude Tessier, VP, Business Development, Kyn Therapeutics
  • Ken Zwicker, Executive Director, IP& Licensing, Technology Development Office, BU University

The seminar is free but you have to register on this link 

Refreshments and Networking at 3:30 – 4:00 PM

Discussion 4:00 – 5:00 PM

Bios:

Christine Jost-Price

Christine has served as Director, Sanofi Genzyme Transactions at Sanofi since January 2017. In this role, she is responsible for negotiating agreements primarily with academics and biotech in the early stage research space. Prior to this role, she held the position of Director, NA Alliance Management at Sanofi for 2 years. In that role, Christine managed multiple academic and corporate alliances.   Christine came to Sanofi from academic technology transfer, serving as Associate Director in the Technology Ventures Office of Beth Israel Deaconess Medical Center for 16 years.  In that role, she was responsible for evaluation of inventions, as well as management and active marketing of a large patent portfolio. In addition, she negotiated sponsored research and license agreements, and served as alliance manager for several major pharmaceutical alliances. Christine holds a PhD in Molecular Biology and Genetics, with a focus on tumor suppressor genes, from Harvard Medical School.

Aaron Schwartz

Aaron has been a Director in Novo Nordisk’s Search & Evaluation team in Global Drug Discovery  since 2016.  In this capacity, Aaron is responsible for the search an evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years.  During this time, he worked on license and sponsored research agreements with life sciences companies from startups to big biotech/pharma and everything in between.  He also managed a portfolio of over 650 technologies.  Before Aaron’s time at MIT, he was a management consultant to big pharma and a startup.  Aaron has an undergrad degree in biology from the University of Chicago and a Masters degree in biology from MIT.

Maude Tessier

Dr. Maude Tessier brings over 12 years of business development, licensing and alliance management experience in pharma, biotech and academia. Most recently, she served as Executive Director, Business Development & Licensing at Merck & Co, leading oncology partnering in the Boston Innovation Hub. Prior to joining Merck, Maude was Assistant Director, Business Development and Strategic Initiatives in the Technology and Innovation Development Office at Boston Children’s Hospital. In this role, she forged discovery alliances with industry partners and also built and managed the Marketing & Communications team. Maude began her career at Xanthus Pharmaceuticals, a small venture-backed oncology biotech company in Cambridge, Mass., where she had key roles in Business Development and Program Management of a Phase 3 asset leading to its eventual FDA approval. Maude is Co-Chair of the Business Development & Finance Working Group at MassBio. She holds a B.Sc. in Biochemistry from McGill University and a Ph.D. from the Department of Medical Biophysics at the University of Toronto.

Ken Zwicker

Dr. Zwicker joined the Technology Development Office (OTD) in April 2016. Ken is responsible for all intellectual property and technology licensing matters arising from the Boston University Charles River Campus, the Boston University Medical School, the Goldman School of Dental Medicine, and the Boston Medical Center. Ken is an experienced patent attorney across all areas of technology, with particular expertise in life sciences intellectual property. Ken has extensive experience in both private practice and as in-house counsel.
Before joining the OTD, Ken was Partner at a major Boston law firm, where he counseled a broad spectrum of clients from fortune 200 companies, to academic institutions, to local start-ups and non-profit organizations in the areas of intellectual property assessment, patent strategy, prosecution, protection, licensing, acquisition, and enforcement. Prior to that, Ken was in-house counsel at Abbott Labs. At Abbott, Ken served as Division Patent Counsel, and headed the patent department of Abbott Bioresearch Center (now AbbVie). In that role, Ken directed the Abbott Labs immunoscience pharmaceutical products patent portfolio, including Abbott’s blockbuster drug, Humira®, the first fully human therapeutic antibody. In addition, Ken established and directed Abbott Labs global intellectual property strategy for therapeutic biologics R&D, process science, and commercial manufacture.

 

 

 

 

 

 

Top